title: Expression and significance of hypoxia inducible factor-1α and lysyl oxidase in non-small cell lung cancer.
abstract: OBJECTIVE
  To detect expression of hypoxia inducible factor-1α (HIF-1α) and lysyl oxidase (LOX) in non-small cell lung cancer (NSCLC) and explore their roles in prognosis.
  
  
  METHODS
  The mRNA levels of HIF-1α and LOX were investigated by real-time reverse-transcriptase polymerase chain reaction in 40 cases of tumour and paired normal tissues. In addition, protein expression of HIF-1α and LOX was examined by immunohistochemistry in 82 cases of tumour and 45 paired normal tissues. The relationship between HIF-1α or LOX and clinicopathologic characteristics, as well as the correlation between HIF-1α and LOX, were also examined. Kaplan-Meier survival curves and the log-rank test were used to analyze progression-free survival.
  
  
  RESULTS
  HIF-1α or LOX mRNA levels in tumor tissues was significantly higher than those in paired normal tissues (p<0.01). Positive HIF-1α or LOX protein expression in tumor tissues was noted in 46/82 (56.1%) and 49/82 (59.8%) of the cases, respectively, being significantly higher than those in paired normal tissues (p<0.05). There was significant correlation between the expression of HIF-1α or LOX and tumor size, lymph node metastasis and pathological stage (p<0.05). The expression of HIF-1α and LOX had a significant inverse impact on survival of patients with NSCLC.
  
  
  CONCLUSIONS
  HIF-1α and LOX may play a pivotal role in the development of NSCLC, and may act in synergy to promote the progression of NSCLC.
authors.affiliation: Department of Thoracic Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
authors.forename: Wei
authors.initials: W
authors.lastname: Ping
authors.forename: Wen-Yang
authors.initials: WY
authors.lastname: Jiang
authors.forename: Wen-Shu
authors.initials: WS
authors.lastname: Chen
authors.forename: Wei
authors.initials: W
authors.lastname: Sun
authors.forename: Xiang-Ning
authors.initials: XN
authors.lastname: Fu
mesh_terms: D000230:Adenocarcinoma / Q000378:metabolism / Q000401:mortality* / Q000473:pathology; D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000235:genetics / Q000378:metabolism; D002289:Carcinoma, Non-Small-Cell Lung / Q000378:metabolism / Q000401:mortality* / Q000473:pathology; D002294:Carcinoma, Squamous Cell / Q000378:metabolism / Q000401:mortality* / Q000473:pathology; D016022:Case-Control Studies; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D051795:Hypoxia-Inducible Factor 1, alpha Subunit / Q000378:metabolism*; D007124:Immunoenzyme Techniques; D008175:Lung Neoplasms / Q000378:metabolism / Q000401:mortality* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000378:metabolism / Q000401:mortality* / Q000473:pathology; D009367:Neoplasm Staging; D011379:Prognosis; D008249:Protein-Lysine 6-Oxidase / Q000378:metabolism*; D012333:RNA, Messenger / Q000235:genetics; D060888:Real-Time Polymerase Chain Reaction; D020133:Reverse Transcriptase Polymerase Chain Reaction; D015996:Survival Rate
chemical_list: D014408:Biomarkers, Tumor; C497442:HIF1A protein, human; D051795:Hypoxia-Inducible Factor 1, alpha Subunit; D012333:RNA, Messenger; D008249:Protein-Lysine 6-Oxidase